ALIMTA

This brand name is authorized in United States. It is also authorized in Austria, Brazil, Canada, Cyprus, Ecuador, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Japan, Lithuania, Mexico, Netherlands, New Zealand, Poland, Romania, Singapore, South Africa, Spain, Tunisia, Turkey, UK.

Active ingredients

The drug ALIMTA contains one active pharmaceutical ingredient (API):

1
UNII 9T47E4OM16 - PEMETREXED DISODIUM HEPTAHYDRATE
 

Pemetrexed is a folate analog metabolic inhibitor that exerts its action by disrupting folate-dependent metabolic processes essential for cell replication. In vitro studies have shown that pemetrexed inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), glycinamide ribonucleotide formyltransferase (GARFT) and and to a lesser extent aminoimidazole carboxamide ribonucleotide formyltransferase (AICARFT), which are folate-dependent enzymes involved in the de novo biosynthesis of thymidine and purine nucleotides. Pemetrexed is taken into cells by membrane carriers such as the reduced folate carrier and membrane folate binding protein transport systems. Once in the cell, pemetrexed is converted to polyglutamate forms by the enzyme folylpolyglutamate synthetase. The polyglutamate forms are retained in cells and are inhibitors of TS and GARFT. Polyglutamation is a time- and concentration-dependent process that occurs in tumor cells and, is thought to occur to a lesser extent, in normal tissues. Polyglutamated metabolites are thought to have an increased intracellular half-life resulting in prolonged drug action in malignant cells.

 
Read more about Pemetrexed

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group Classification
L01BA04 Pemetrexed L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01B Antimetabolites → L01BA Folic acid analogues
Discover more medicines within L01BA04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
BR Câmara de Regulação do Mercado de Medicamentos 507603401154210, 507603402150219
CA Health Products and Food Branch 02253437, 02306433
EC Agencia Nacional de Regulación, Control y Vigilancia Sanitaria 29014-09-09, 6201-MEE-0421
EE Ravimiamet 1187849, 1362529
ES Centro de información online de medicamentos de la AEMPS 04290001, 04290002
FI Lääkealan turvallisuus- ja kehittämiskeskus 019797, 120062
FR Base de données publique des médicaments 67323808, 67713231
GB Medicines & Healthcare Products Regulatory Agency 146759, 89935
HK Department of Health Drug Office 53331, 58016
IL מִשְׂרַד הַבְּרִיאוּת 7336
JP 医薬品医療機器総合機構 4229401D1020, 4229401D2026
LT Valstybinė vaistų kontrolės tarnyba 1027355, 1050849
MX Comisión Federal para la Protección contra Riesgos Sanitarios 125M2005
NL Z-Index G-Standaard, PRK 138061, 138088
NZ Medicines and Medical Devices Safety Authority 11451, 13307
PL Rejestru Produktów Leczniczych 100100780, 100104794
RO Agenția Națională a Medicamentului și a Dispozitivelor Medicale W42003001, W52526001
SG Health Sciences Authority 13042P, 13480P
TN Direction de la Pharmacie et du Médicament 4323032H
TR İlaç ve Tıbbi Cihaz Kurumu 8699673261133, 8699673261140
US FDA, National Drug Code 0002-7623, 0002-7640
ZA Health Products Regulatory Authority 42/26/0448, A39/26/0028

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.